Decibel Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$87.3M
Industry:Biotech
Founded:2015
Lead Investor(s):Third Rock Ventures LLC

Industry Ranking

Estimated Revenue & Financials

  • Decibel Therapeutics's estimated annual revenue is currently $9.3M per year.
  • Decibel Therapeutics received $55.0M in venture funding in June 2018.
  • Decibel Therapeutics's estimated revenue per employee is $155,000
  • Decibel Therapeutics's total funding is $87.3M.

Employee Data

  • Decibel Therapeutics has 60 Employees.
  • Decibel Therapeutics grew their employee count by -33% last year.
  • Decibel Therapeutics currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Ultivue
$8.7M56-12%N/AN/A
Ohana Bioscienc...
$8.7M5660%N/AN/A
Compass Therape...
$16.4M10614%N/AN/A
Cell Signaling ...
$89.4M577N/AN/AN/A
Momenta Pharmac...
N/A220N/AN/AN/A
Emulate
$15.3M99-17%N/AN/A
ArQule
N/A94N/AN/AN/A
Hamilton Storag...
$17.2M1119%N/AN/A
Alnylam Pharmac...
$74.9M127731%N/AN/A
Transgenomic
N/A47N/AN/AN/A
Missing a competitor? Contribute!?
Submit

Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing. Hearing loss is the most prevalent form of sensory impairment. It is estimated that 50 million people in the U.S., and 360 million people worldwide, suffer from some type of hearing loss. Hearing disorders affect people of all ages and can have a profound impact on quality of life. By combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques, Decibel is pioneering a comprehensive approach to defining and treating the underlying biological causes of hearing disorders, and developing a pipeline of breakthrough drugs targeted to specific indications and patients. Founded by the world's preeminent experts in inner ear biology and hearing disorders, Decibel Therapeutics was launched in 2015 by Third Rock Ventures and SR One and is headquartered in Boston, Mass. For more information and to browse career opportunities at Decibel Therapeutics, please visit decibeltx.com.

keywords:Biotechnology,Healthcare,Medical Devices,Medical Diagnostics

60

Number of Employees

$9.3M

Revenue (est)

1

Current Jobs

-33%

Employee Growth %

$87.3M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
John KeiltyChief Data Sciences OfficerEmail Available
Michael SuChief Scientific OfficerEmail Available
Fuxin ShiDirectorEmail Available
CHRISTOPHER HRENSenior Director, Corporate DevelopmentEmail Available
Jason KroppAssociate Director, Cmc OperationsEmail Available
Elaine CopeSenior Director, FacilitiesEmail Available
Ada Silos-santiagoVP Pharmacology
William OemlerSenior Manager, Software Engineering
Daniel RosanVice President Corporate DevelopmentEmail Available
Adam PalermoSenior Director And Head Of Genomics And Computational BiologyEmail Available

Decibel Therapeutics News

09/07/2019 - Frequency Plans IPO for Hearing Loss Drug & More ...

Frequency Therapeutics is developing a hearing loss drug that taps into the ... Another Boston firm, Decibel Therapeutics, is developing small ...

09/08/2019 - Biotech execs criticize 'atmosphere of intimidation' amid ...

The letter was written together by Ovid Therapeutics CEO and ... Acorda Therapeutics CEO Ron Cohen, Decibel Therapeutics CEO Steven ...

06/26/2019 - Decibel Therapeutics Appoints Healthcare Industry Veteran ...

BOSTON--(BUSINESS WIRE)-- Decibel Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for hearing loss ...

Decibel Therapeutics Funding

DateAmountRoundLead InvestorsReference
2015-10-16$52.0MAThird Rock Ventures LLCArticle
2018-06-20$55.0MCMultipleArticle

Decibel Therapeutics Executive Hires

DateNameTitleReference
2016-07-14Steven H HoltzmanPresident & CEOArticle
2016-09-08Michael SuChief Scientific OfficerArticle
2017-01-19John KeiltyChief Data Sciences OfficerArticle
2019-02-06Peter WeberChief Medical OfficerArticle